Make an Appointment
HMH Partners with Medtech Company Neosoma for Innovation in Brain Tumor Treatment Research
![](/-/media/Project/HMH/HMH/MAESTRO/wp-content/uploads/2023/02/iStock-1292254104.jpg)
What You Need To Know
- HMH’s new partnership with Neosoma, a Boston-based medtech company that uses artificial intelligence to research and treat brain tumors, encompasses data-sharing, clinical research and strategic investment by HMH.
- Neosoma’s innovative method of imaging, tracking and collecting data on numerous types of brain tumors, including glioblastomas, will help HMH physicians with some of the most difficult medical diagnoses.
- Neosoma recently received FDA clearance for an AI-based neuro-health software device that produces precise and accurate brain tumor analysis on MRIs.
JFK Physicians Will Be First To Use The New Technology
HMH physicians will use Neosoma’s software in clinical practice, beginning with those at Hackensack Meridian JFK University Medical Center – leaders in brain tumor surgery and treatment. The technology will help physicians:- Plan procedures
- Assess post-procedural results
- Guide chemo and immunotherapy treatments
- Track patients longitudinally
- Avoid unnecessary surgeries and interruptions in care
- Improve treatment and patient experience